Juventas Therapeutics doses first patient in Phase II Trial
CLEVELAND, Aug. 20, 2012 - Juventas Therapeutics, a Glengary portfolio company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial. The 90-patient, placebo-controlled, randomized double-blinded Phase II study is evaluating the safety and efficacy for JVS-100 in patients with late stage heart failure.
"The initiation of this trial marks an important step forward for Juventas Therapeutics," states Marc Penn, M.D., Ph.D. Founder of Juventas and the Director of the Summa Cardiovascular Institute at Summa Health Systems. "We established the Company based on a hypothesis that cell therapy could be distilled down to factor-based approaches, which would be clinically-beneficial while reducing cost and complexity associated with producing and delivering adult stem cells. It is exciting to see those early scientific discoveries translate into potential therapeutics."
For the complete story click here.